728: AR-3D PSMA-PET guided robot-assisted lymphnode dissection- Pietro Piazza
This is one of the entries accepted for adjudication for the 2026 KS Innovation Awards, sponsored by the Vattikuti Foundation. Posting here does not imply being a Finalist.
Here is the Abstract:
AR-3D PSMA-PET guided robot-assisted lymphnode dissection
Presenter:Pietro Piazza, assistant professor
University of Bologna
Pietro.piazza2@unibo.it
Purpose
Identifying metastatic lymph nodes outside standard dissection boundaries is challenging during robotic prostatectomy. We evaluated the feasibility of augmented reality navigation using three- dimensional models derived from prostate-specific membrane antigen positron emission tomography (PSMA-PET) to guide lymph node dissection.
Methods
This single-center, prospective, non-comparative study included 13 patients with high-risk prostate cancer and miN1-2 or miM1a disease on PSMA-PET. Patients underwent robot-assisted radical prostatectomy with augmented reality guided lymph node dissection between December 2022 and June 2024. Three-dimensional models were segmented from preoperative PSMA-PET images using Mimics Medical software. Intraoperative stereoscopic overlays were manually aligned by a biomedical engineer to guide identification of suspicious nodes.
Results
Preoperative imaging identified suspicious lymph nodes outside the extended pelvic lymph node dissection template in 30% of patients. Histopathological analysis confirmed metastases in these regions in 23% of patients. Per-region analysis yielded 69% sensitivity, 90% specificity, and an area under the receiver operating characteristic curve of 0.79. Limitations included the small cohort, absence of a comparator, limited PSMA-PET resolution for micrometastases, and manual model
alignment.
Conclusions
Augmented reality guided lymph node dissection was feasible and enabled intraoperative localization of suspicious nodes, including those outside standard dissection boundaries, without additional intraoperative radiotracer injection. Larger comparative studies with long-term follow-up are required to establish oncological benefit.